AI Consensus Investment Thesis
Sana Biotechnology (SANA) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
NEUTRAL
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
NEUTRAL$3.18
+2.4%5-Year
NEUTRAL$5.39
+74.0%Latest flagship insight
Platform Validation Clashes With Relentless Balance Sheet Dilution Pressure
High consensus confirms the biological validity of engineered hypoimmune cloaking for cell therapies, led by durable islet persistence data. However, sharp divergence surrounds whether clinical progress can outrun structural balance-sheet dilution, given zero recurring revenues, continuous equity issuance, and a finite cash runway.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Universal Investor (Polymath), Machiavelli (Insider), Ray Dalio (Strategist), Sherlock Holmes (Whistleblower), Elon Musk (Visionary), Warren Buffett (Value Purist), Michael Burry (Vulture), Superintelligence (Anthropologist), J.P. Morgan (Titan). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Sana Biotechnology at the forecast anchor (2026-09-18): $17,401 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 3.05 | -1.70% | -1.70% | Long-term data presentations at medical congresses reinforce platform biological credibility, but year-end tax-loss selling, elevated discount rates, and persistent at-the-market equity issuance dampen upward price momentum. |
| Q1 2027 | 3.19 | +4.84% | +3.05% | Anticipation around the impending regulatory clearance for lead diabetes trials sparks selective accumulation, though ongoing cash burn and macroeconomic rate tightness keep quarterly equity appreciation tightly constrained. |
| Q2 2027 | 3.34 | +4.54% | +7.73% | Regulatory clearance of the investigational new drug application triggers positive sentiment, validating the preclinical package and attracting speculative capital despite continuous baseline operational expenditures. |
| Q3 2027 | 3.18 | -4.90% | +2.45% | With cash runway narrowing past mid-2027, management executes a necessary equity financing round. Dilutive share issuance and price concessions create immediate supply overhang, temporarily suppressing per-share performance. |
| Q4 2027 | 3.36 | +5.68% | +8.26% | Initial human safety observations and preliminary cohort biomarker data confirm absence of acute immune rejection, sparking a relief rally as early biological proof-of-concept solidifies across the clinical portfolio. |
| Q1 2028 | 3.58 | +6.70% | +15.51% | Dosing across clinical trial sites proceeds smoothly, but rising trial maintenance costs and the absence of immediate multi-patient efficacy readouts produce a phase of modest valuation consolidation. |
| Q2 2028 | 3.76 | +5.09% | +21.39% | Early biomarker data demonstrating detectable stimulated C-peptide secretion across treated cohorts validates functional islet engraftment, igniting aggressive short covering and substantial speculative multiple expansion. |
| Q3 2028 | 3.74 | -0.50% | +20.79% | Management capitalizes on recent clinical enthusiasm to tap secondary equity markets for working capital. The resulting mechanical dilution and summer trading illiquidity cool short-term market momentum. |
| Q4 2028 | 3.91 | +4.35% | +26.04% | Preclinical and early clinical progress in targeted in vivo delivery candidates diversifies platform optionality, attracting institutional biopharma specialists and lifting overall risk-adjusted enterprise valuation. |
| Q1 2029 | 4.17 | +6.82% | +34.64% | Gradual macroeconomic easing lowers hurdle discount rates for pre-revenue biotechnology, allowing stable trial site enrollment and consistent laboratory milestone achievements to support moderate valuation gains. |
| Q2 2029 | 4.34 | +3.96% | +39.97% | Extended clinical follow-up confirming sustained exogenous insulin reduction in treated patients prompts aggressive institutional accumulation and validates the immunosuppression-free commercial thesis. |
| Q3 2029 | 4.40 | +1.33% | +41.84% | Capital requirements for expanding multicenter trial operations necessitate opportunistic equity distribution, creating routine digestion of new share supply that temporarily pauses upward valuation momentum. |
| Q4 2029 | 4.48 | +1.99% | +44.66% | Presentations of durable multi-patient functional data at major medical conferences re-energize takeover speculation, solidifying competitive standing against rival cell therapies requiring chronic systemic immunosuppression. |
| Q1 2030 | 4.77 | +6.47% | +54.02% | Constructive regulatory alignment regarding pivotal registration endpoints clarifies the commercialization pathway, compressing duration risk and supporting firm valuation accretion across specialized healthcare portfolios. |
| Q2 2030 | 4.77 | +0.01% | +54.03% | Execution of an international regional co-development partnership delivers substantial upfront non-dilutive milestone capital, easing structural solvency overhangs and propelling shares higher on pharmaceutical endorsement. |
| Q3 2030 | 4.83 | +1.22% | +55.91% | Post-partnership consolidation sets in as the market digests operational trial parameters and prepares for capital-intensive pivotal study enrollments, leading to measured profit-taking. |
| Q4 2030 | 5.03 | +3.99% | +62.13% | Advancement of the in vivo fusosome program into expanded autoimmune trials broadens therapeutic addressable markets, reinforcing platform scalability and providing renewed long-term valuation support. |
| Q1 2031 | 5.17 | +2.78% | +66.64% | First patient dosing across global pivotal trial centers sustains constructive investor interest, though ongoing development expenditures keep net earnings in structural deficit as expected. |
| Q2 2031 | 5.22 | +1.06% | +68.40% | Mid-stage clinical updates confirming durable therapeutic cell persistence reinforce platform differentiation, while the significantly expanded share count caps per-share appreciation relative to gross scientific gains. |
| Q3 2031 | 5.39 | +3.33% | +74.01% | Pivotal study interim safety reviews pass cleanly, positioning lead programs for impending regulatory filings and establishing a stable five-year terminal platform valuation across the diluted equity base. |
The central investment thesis is defined by an acute structural tension: genuine biological proof-of-concept versus severe per-share equity debasement. Peer-reviewed clinical evidence confirming 14-month pancreatic islet survival without systemic immunosuppression substantiates the hypoimmune platform's genetic cloaking architecture. This de-risks lead candidate SC451 in type 1 diabetes and supports in vivo fusosome vector optionality in SG293. However, with trailing twelve-month free cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry near $135 million against $160.5 million in reserves, the operational runway extends only into mid-2027. Under elevated discount rates, recurring at-the-market equity financing and sizable contingent-consideration liabilities systematically dilute common equity claims.
Key insights
- Platform biological validation creates legitimate horizontal optionality across regenerative medicine, yet per-share value capture remains heavily constrained by relentless share count expansion.
- Outsourcing manufacturing to contract organizations preserves immediate liquidity but increases batch-level operational friction and transfers long-term unit-cost economics to third parties.
- Non-dilutive partnership upfronts represent the singular mechanism capable of breaking the reflexive dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry cycle before cash depletion forces distressed financing.
This company has developed a groundbreaking way to hide transplanted cells from the immune system, showing success in a diabetes patient without using anti-rejection drugs. This discovery gives the company massive medical potential. However, it makes zero product revenue and burns through cash rapidly, leaving only enough money to operate into mid-2027. To keep testing its treatments, management must repeatedly issue new shares of stock. This continuous dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry increases the total share supply, meaning that even when the underlying science succeeds, everyday shareholders may see their individual gains heavily watered down.
Key insights
- Groundbreaking cell-cloaking science proves the technology works, but clinical trials take years and cost hundreds of millions.
- Continuous stock sales to fund operations dilute current shareholders, capping individual per-share investment gains.
- Securing a major pharmaceutical partnership with upfront cash is crucial to eliminate ongoing bankruptcy risks.
Deep Dive
Prevailing market sentiment treats the company as an uninvestable pandemic-era biotech bubble casualty stranded in a higher-for-longer interest rate regimeinterest rate regimeA persistent pattern in policy rates and market yields that shapes borrowing costs, discount rates, and asset values.View full glossary entry. Consensus models anchor to the rapid cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry, zero recurring revenues, and a cash runway expiring by mid-2027. Investors largely dismiss the 14-month diabetes islet data as an unscalable single-patient anomaly, assuming relentless at-the-market share dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry will wipe out common shareholders before commercialization.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Prevailing market sentiment treats the company as an uninvestable pandemic-era biotech bubble casualty stranded in a higher-for-longer interest rate regimeinterest rate regimeA persistent pattern in policy rates and market yields that shapes borrowing costs, discount rates, and asset values.View full glossary entry. Consensus models anchor to the rapid cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry, zero recurring revenues, and a cash runway expiring by mid-2027. Investors largely dismiss the 14-month diabetes islet data as an unscalable single-patient anomaly, assuming relentless at-the-market share dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry will wipe out common shareholders before commercialization.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underestimates the biological reality and horizontal licensing optionality of the hypoimmune platform, creating an underpricing gap at current valuation levels. While the market views the stock strictly as a distressed cash-burn furnace, peer-reviewed human data prove that disrupting MHC class I/II while overexpressing CD47 evades host immune destruction without immunosuppression. Wall Street overlooks that this validated biological cloaking solves the universal bottleneck of allogeneic cell therapy, providing massive strategic takeout optionality.
Repricing Catalyst
What could make the market recognize and close that gap? The primary convergence catalyst is the regulatory clearance and initial multi-patient Phase 1 safety and C-peptide biomarker readout for lead diabetes candidate SC451 between late 2026 and 2027. Demonstrating endogenous insulin secretion without immunosuppressive pharmacotherapy across multiple patients would decisively validate platform scalability. This objective clinical proof would force institutional analysts to revalue the company from a distressed research lab into an indispensable biopharma platform.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- High Erratic
- Cycle position
- Stabilization
Sentiment uniformly reflects deep risk aversion toward pre-commercial biotech cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry. The primary disagreement centers on whether the stock is carving out a cyclical stabilization base following pipeline restructuring, or entering a structural reversal driven by terminal shareholder dilution.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macroeconomic regimemacroeconomic regimeThe prevailing set of economic conditions including interest rates and inflation that influence asset pricing.View full glossary entry of benchmark interest rates near 4.00% and ten-year Treasury yields hovering around 5.0% acts as a fierce headwind. Pre-revenue clinical biotechnology represents the longest-duration equity asset class. Elevated discount rates compress terminal cash-flow multiples, while risk-averse capital markets make equity-financed clinical trial development increasingly expensive, raising the dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry cost per dollar of operational cash burned.
Advisor Disagreement
What do our AI Advisors disagree about most? The decisive disagreement centers on whether extraordinary scientific platform de-risking can outpace relentless equity dilutionequity dilutionThe reduction in ownership percentage for existing shareholders caused by the issuance of new shares.View full glossary entry before the mid-2027 cash runway boundary. Bullish perspectives argue that human proof-of-concept in immunosuppression-free islet survival creates an indispensable platform monopoly that will unlock hundreds of millions in non-dilutive pharmaceutical partnership upfronts. Bearish assessments emphasize forensic cash-flow arithmetic, contending that expanding share counts toward 400 million units permanently erodes per-share intrinsic valueintrinsic valueThe estimated true worth of a business or asset based on fundamentals instead of short-term market mood.View full glossary entry. Resolving this tension requires tracking whether initial multi-patient C-peptide data arrives before cash reserves drop below $80 million.
Base-Case Forces
Event Risk ScoreVery High94/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Hypoimmune biological cloaking validation | Innovation And Product | +45% | +15% | Peer-reviewed publication in the New England Journal of Medicine demonstrated 14-month islet graft survival and insulin production without systemic immunosuppression. Disrupting MHC class I/II and overexpressing CD47 provides empirical biological proof that engineered cells can evade immune destruction, substantially de-risking lead clinical programs across diabetes and autoimmune therapeutics. |
| In vivo fusosome delivery disruption | Competitive Positioning | +30% | +10% | The CD8-targeted fusosome platform, led by SG293, reprogrammes immune cells directly inside the patient, bypassing expensive ex-vivo bioreactor culturing and toxic preconditioning chemotherapy. Demonstrating profound systemic B-cell depletion in non-human primates establishes substantial long-term cost moats and positions the company to license genetic delivery architecture to pharmaceutical partners. |
| Asset-light contract manufacturing pivot | Operational Efficiency | +20% | +25% | Management halted internal manufacturing facility buildouts, taking non-cash impairments to transition clinical cell production entirely to specialized contract development and manufacturing organizations. This structural restructuring curtailed annual operating cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry from over $270 million to approximately $135 million, preserving balance-sheet liquidity to fund critical human clinical inflection milestones. |
| Tier-one institutional clinical alliances | Capital Allocation | +18% | +15% | Direct equity investment and strategic clinical collaboration with the Mayo Clinic provide elite clinical infrastructure, patient recruitment priority, and third-party scientific validation. Aligning with premier healthcare institutions derisks trial execution for lead programs and opens avenues for non-dilutive co-development and regional out-licensing structures. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Persistent dilutive share issuance | Capital Allocation | -38% | -15% | Operating as a pre-commercial entity with zero revenue and trailing cash deficits of $135 million requires continuous external equity funding. Management's systematic reliance on at-the-market facilities relentlessly expands the outstanding share count toward 400 million units, mechanically transferring platform gains to underwriting syndicates and capping per-share equity appreciation. |
| Restrictive high discount-rate regime | Macroeconomic And Macrofinancial | -24% | -10% | With central bank benchmark rates near 4.00% and ten-year Treasury yields pressing 5.0%, long-duration clinical biotech assets face severe net present value compression. Elevated risk-free hurdles restrict institutional venture liquidity, penalizing chronic cash-burning developers and forcing management to accept steep valuation discounts on secondary equity offerings. |
| Complex stem-cell manufacturing scaling | Operational Efficiency | -20% | -15% | Translating cadaveric islet cell survival into scalable, pluripotent stem-cell-derived products involves complex biological and regulatory hurdles. Relying entirely on contract manufacturing organizations introduces potential batch-to-batch yield variances, scheduling bottlenecks, and high per-batch clinical production expenses that threaten developmental timelines and cash consumption. |
| Intense cell therapy class competition | Competitive Positioning | -18% | -15% | Well-capitalized pharmaceutical giants, including Vertex Pharmaceuticals, are aggressively advancing rival stem-cell-derived islet programs and encapsulated cell therapies. Competitors command vastly superior commercial infrastructure and balance-sheet liquidity, which threatens to compress future market share, reduce pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry, and weaken prospective licensing royalty negotiations. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Catastrophic clinical graft failure event | 32% | -75% | Expanded clinical trial cohorts encounter late-onset cellular graft rejection, immune sensitization, or genomic instability leading to teratoma formation by 2028. Such an adverse event would prompt an immediate regulatory clinical hold, dismantling the foundational hypoimmune platform thesis and eviscerating corporate market capitalizationmarket capitalizationThe market value of an asset or company, commonly calculated for a company as share price multiplied by shares outstanding.View full glossary entry toward net cash value. |
| Mid-2027 runway wall liquidity freeze | 28% | -65% | Macroeconomic stagflationstagflationAn economic condition characterized by stagnant growth, high unemployment, and high inflation.View full glossary entry and persistent 5% bond yields freeze biotech secondary equity markets while liquid reserves deplete below six months of operating runway by early 2027. Unable to execute at-the-market offerings, management is forced into distressed recapitalizations, punitive warrant structures, or bankruptcy restructuring that wipes out common equity. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Curative insulin independence in diabetes | 28% | +160% | Early Phase 1 cohort data for lead candidate SC451 demonstrates robust, durable insulin independence without immunosuppressive regimens in type 1 diabetes patients by 2028. Restoring endogenous glycemic control in humans validates an unassailable commercial monopoly in regenerative endocrinology, triggering an immediate institutional valuation re-rating. |
| Transformative big pharma buyout offer | 22% | +120% | A multinational pharmaceutical giant seeking to bypass allogeneic immunogenicity barriers launches an outright acquisition of the company following confirmed in vivo fusosome or multi-patient islet data by 2029. A premium buyout offer eliminates financing dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry and immediately crystallizes intrinsic platform value for common shareholders. |
Company Financial Analysis
Sana Biotechnology Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
The company operates as a pure pre-commercial biotechnology developer, generating zero recurring product revenue while reporting a trailing twelve-month net loss of $212 million through mid-2026. Headline losses narrowed noticeably from historical peaks exceeding $340 million, but this improvement reflects strict survival measures rather than operational growth. Management aggressively restructured operations, halting early-stage oncology trials to protect remaining capital. Free cash flow burn has stabilized at approximately $135 million annually. While slowing cash consumption buys critical operational time, the absence of commercial revenue means the business remains completely dependent on external funding. Reported bottom-line improvements stem largely from non-cash accounting adjustments rather than commercial sales.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 0 | USD -244.2M | USD -144.8M |
| 2024 | USD 0 | USD -266.8M | USD -256.6M |
| 2023 | USD 0 | USD -283.3M | USD -273.6M |
| 2022 | USD 0 | USD -266.4M | USD -310.9M |
| 2021 | USD 0 | USD -344.2M | USD -280.9M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | -- | TTM | Loss-making | USD / USD |
| 2024 | -- | TTM | Loss-making | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | -- | Annual | Loss-making | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Traditional profit margin metrics are entirely undefined because the business produces no commercial revenue. Trailing twelve-month operating losses stand near $208 million, while return on equity remains deeply negative at minus 152%. These negative metrics reflect the heavy expense of conducting advanced cellular research without incoming customer receipts. Recent reductions in operating deficits reflect corporate austerity and workforce rationalization rather than genuine profit leverage. If its stem-cell therapies successfully achieve commercial regulatory approval, off-the-shelf allogeneic manufacturing could eventually produce software-like profit margins. Until human trials prove definitive efficacy, however, profitability remains purely theoretical.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD -191M | -- | -- |
| 2024 | USD -272.7M | -- | -- |
| 2023 | USD -293.1M | -- | -- |
| 2022 | USD -272.6M | -- | -- |
| 2021 | USD -356.9M | -- | -- |
Balance sheet and leverage
AI Review
The company held $160.5 million in cash and liquid securities at the end of the second quarter of 2026, bolstered by equity sales and a $25 million investment from the Mayo Clinic. While the company carries minimal traditional bank debt, its liquid reserves provide an operational runway extending only into mid-2027 against its current spending rate. Headline liquidity conceals significant off-balance-sheet commitments, including over $150 million in contingent liabilities and success payments linked to pipeline progress. Because the business generates no cash flow, the balance sheet acts as a ticking clock that forces ongoing stock issuance to avert insolvency.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 78.9M | USD 138.4M | USD 7M net debt | 1.89x |
| 2024 | USD 94.2M | USD 152.5M | USD 33.4M net cash | 3.54x |
| 2023 | USD 104.1M | USD 205.2M | USD 29.4M net cash | 3.31x |
| 2022 | USD 108.3M | USD 424M | USD 68.5M net cash | 3.99x |
| 2021 | USD 110.9M | USD 551M | USD 142.1M net cash | 5.62x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management has executed an aggressive retreat from physical infrastructure spending. Capital expenditures dropped to negligible levels after the company halted the buildout of its internal manufacturing facility in Bothell, taking substantial non-cash write-downs. Instead of building expensive cleanrooms, the company now relies entirely on third-party commercial contract manufacturers for clinical cell supplies. This capital discipline preserved vital liquidity during a period of high interest rates, directing scarce dollars into core laboratory milestones. However, outsourcing clinical production trades fixed overhead for higher variable per-batch costs and creates operational dependency on third-party manufacturing schedules as trials expand.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 938K | USD 132M |
| 2024 | USD 33.4M | USD 208.7M |
| 2023 | USD 20M | USD 219.8M |
| 2022 | USD 20.9M | USD 201M |
| 2021 | USD 29.9M | USD 306.5M |
Quarterly Forecast Scenarios
Sana Biotechnology Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $2.759 | $3.0491 | $3.348 | $750.26 | |
| $2.5098 | $3.1166 | $3.7498 | $736.44 | |
| $2.6603 | $3.2412 | $3.755 | $743.40 | |
| $2.5273 | $3.1559 | $4.0104 | $755.15 | |
| $2.2746 | $3.2964 | $3.9652 | $776.22 | |
| $2.1154 | $3.5172 | $4.56 | $787.13 | |
| $2.2846 | $3.7679 | $4.7341 | $802.83 | |
| $2.1475 | $3.7457 | $4.8865 | $812.05 | |
| $2.0616 | $3.9435 | $5.4729 | $839.18 | |
| $1.8967 | $4.1831 | $5.6338 | $850.50 | |
| $1.9915 | $4.4539 | $6.4225 | $872.39 | |
| $1.872 | $4.5221 | $6.4167 | $885.51 | |
| $1.7784 | $4.692 | $7.0776 | $909.56 | |
| $1.7073 | $4.9544 | $7.573 | $916.13 | |
| $1.8268 | $5.0764 | $8.4818 | $936.51 | |
| $1.7355 | $5.1386 | $7.8881 | $947.34 | |
| $1.6834 | $5.3989 | $8.9924 | $969.59 | |
| $1.6161 | $5.6305 | $9.8017 | $979.99 | |
| $1.6807 | $5.7414 | $10.88 | $999.60 | |
| $1.6471 | $6.0233 | $11.75 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
The consensus weighting reflects a sharp analytical divide between reports grounded in current SEC regulatory filings and those anchored to superseded clinical pipelines. Primary evidence confirms the company pruned legacy ex-vivo CAR-T assets to focus resources on lead candidates SC451 in type 1 diabetes and SG293 in vivo fusosomes, supported by 14-month human islet survival data published in the New England Journal of Medicine. Higher weights are assigned to reports that rigorously isolate cash burn and reconcile operating outlays against non-cash contingent liabilities and milestone success payments. Lower weights penalize opinions that mistakenly treat suspended programs like SC291 as lead assets or project unconstrained multiple expansion without accounting for ongoing share dilution. The strongest credible contrarian insight demonstrates that despite genuine biological validation, persistent dilution via at-the-market facilities systematically transfers platform value from common equity holders to new capital providers under elevated discount-rate regimes.
Universal Investor AI
The Polymath
Opus 5Exhibits superior data freshness and capital structure scrutiny, specifically uncovering $150.8 million in contingent consideration and $24.5 million in success-payment liabilities that senior claims impose on platform progress. Accurately observes that recent clinical publications met market selling due to immediate financing deadlines.
Universal Investor AI
The Polymath
GPT-6 AstraPresents exemplary forensic reconciliation of operating research expenses versus non-cash contingent liability remeasurements from SEC filings. Correctly models reflexive dilution, demonstrating that expanding share counts toward 500 million structurally dampens per-share realization despite technological platform advances.
Michael Burry AI
The Vulture
Gemini 3.8 FlashProvides rigorous forensic balance-sheet examination, emphasizing that trailing free-cash deficits of $135 million require constant share printing that caps per-share realization. Offers a vital contrarian perspective by tracking how share supply expansion toward 400 million units offsets scientific progress.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashPresents strong qualitative depth regarding the transition from artisanal transplants to industrialized stem-cell manufacturing. Accurately highlights competitive threats from rival islet developers and the punitive macro rate environment, balancing optimism on biological cloaking with realistic dilution models.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashDelivers balanced owner-earnings analysis, acknowledging the 14-month UP421 New England Journal of Medicine evidence while rigorously documenting the lack of an economic moat until commercialization. Properly contextualizes the narrowing cash runway into mid-2027.
Elon Musk AI
The Visionary
Gemini 3.8 FlashDemonstrates sound causal analysis of the core hypoimmune biological platform versus ongoing dilutive friction. Accurately identifies the Bothell facility closure, contract manufacturing reliance, and UP421 proof of concept, while reasonably penalizing equity value for recurring at-the-market share issuances.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashThoroughly investigates the forensic reality of the cash runway clock and validates the UP421 clinical data. Accurately notes that abandoning legacy ex vivo CAR-T programs was a rational reallocation of scarce capital toward disruptive in vivo fusosome vectors.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashCaptures the political and institutional dynamics of elite healthcare partnerships, including Mayo Clinic's equity stake. It accurately identifies regulatory gatekeeping risks, though its scenario path leans slightly overly optimistic on the velocity of non-dilutive licensing inflows.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashCorrectly identifies the hypoimmune platform as a strategic chokepoint and captures the Mayo Clinic collaboration. However, it incorporates somewhat aggressive multiple expansion assumptions that downplay the reflexivity of ongoing at-the-market offerings under higher-for-longer capital costs.
Universal Investor AI
The Polymath
Gemini 3.8 FlashEffectively analyzes the operational pivot from internal infrastructure to contract manufacturing organizations. It appropriately flags allogeneic stem-cell scaling bottlenecks, though its terminal multiple assumptions slightly understate the long-term dilution needed to fund multi-center pivotal trials.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashProvides a solid macroeconomic framework evaluating interest-rate duration headwinds on pre-revenue biotech. However, its long-term equity path discounts the dilution treadmill too lightly in earlier quarters, resulting in a slightly delayed recognition of financing frictions.
Universal Investor AI
The Polymath
Gemini 3.8 FlashSuffers from an outdated pipeline premise by treating suspended candidate SC291 in lupus as the central driver rather than recognizing management's operational retrenchment toward SC451 and SG293. Receives low weighting due to factual misalignment with current development priorities.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashRelies heavily on superseded assumptions regarding SC291 autoimmune prioritization instead of primary focus on SC451 diabetes and SG293 fusosomes. Downweighted due to lagging pipeline fidelity, though its assessment of cash burn compression remains methodologically sound.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashSeverely downweighted due to stale pipeline claims centering on deprioritized oncology CAR-T assets, while entirely missing the transformative New England Journal of Medicine diabetes islet clinical disclosures. Its owner-economics framework is valid, but applied to obsolete clinical facts.
Research Provenance
References & Context
This Sana Biotechnology consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 77 deduplicated sources retained for this batch.
- 01www.sec.govsec.gov
- 02Sana’s Cell Therapy Sustains Insulin Production Through 14 Months in a T1D Patient - BioSpacebiospace.com
- 03Sana Biotechnology Announces Follow-On Publication in Theglobenewswire.com
- 04Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updatesglobenewswire.com
- 05Sana Biotechnology at wells fargo healthcare conference: two programs near clinic By Investing.comin.investing.com
- 06Sana Biotechnology at citigroup’s biopharma back to school summit 2026: diabetes push By Investing.cominvesting.com
- 07Sana presents preclinical data on in vivo CAR T therapy SG293 By Investing.cominvesting.com
- 08Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates | INNinvestingnews.com
- 09Vertex Pharmaceuticals | Vertex Reports Second Quarter 2026 Financial Resultsinvestors.vrtx.com
- 10Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression | Sana Biotechnology, Incir.sana.com
- 11Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes | Sana Biotechnology, Incir.sana.com
- 12Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates | Sana Biotechnology, Incir.sana.com
- 13Sana Biotechnology Reports Third Quarter 2025 Financial Results and Business Updates | Sana Biotechnology, Incir.sana.com
- 14Free Trialmarketbeat.com
- 15Sana Biotechnology ($SANA) Stock Hub 2026: SC451, Cash And Catalystsmerlintrader.com
And 62 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
10 fieldscash · commonStockSharesOutstanding · netDebt · shortLongTermDebtTotal · +6 more fields
Cash flow
4 fieldscapitalExpenditures · freeCashFlow · salePurchaseOfStock · totalCashFromOperatingActivities
annual: 2018-12-31–2025-12-31, 8 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.